CRIPTO and neoplasm: In a more general scenario, EV-CRIPTO might interfere with the activity of the other CRIPTO forms (the plasma membrane bound and the soluble ones), and the balance among the different CRIPTO forms might account for the resultant effect of CRIPTO as a tumor agonist or antagonist.